Biotherapy in the Adjuvant Treatment of Colorectal Cancer

The use of adjuvant chemotherapy has improved survival in early-stage colon cancer. Ongoing adjuvant clinical trials are evaluating the addition of targeted therapies to standard chemotherapy regimen. Preliminary results with bevacizumab were disappointing. Also, cetuximab added to chemotherapy does...

Descripción completa

Detalles Bibliográficos
Autores principales: Tazi, El Mehdi, Essadi, Ismail, Boutayeb, Saber, M’rabti, Hind, Errihani, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139728/
https://www.ncbi.nlm.nih.gov/pubmed/27942334
http://dx.doi.org/10.4021/gr335w
_version_ 1782472294753370112
author Tazi, El Mehdi
Essadi, Ismail
Boutayeb, Saber
M’rabti, Hind
Errihani, Hassan
author_facet Tazi, El Mehdi
Essadi, Ismail
Boutayeb, Saber
M’rabti, Hind
Errihani, Hassan
author_sort Tazi, El Mehdi
collection PubMed
description The use of adjuvant chemotherapy has improved survival in early-stage colon cancer. Ongoing adjuvant clinical trials are evaluating the addition of targeted therapies to standard chemotherapy regimen. Preliminary results with bevacizumab were disappointing. Also, cetuximab added to chemotherapy does not seem to be better than chemotherapy alone, even in selected wild-type KRAS populations. A better understanding of mechanisms of action of drugs, tumor biology, and predictive biomarkers are needed to design future adjuvant trials.
format Online
Article
Text
id pubmed-5139728
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-51397282016-12-09 Biotherapy in the Adjuvant Treatment of Colorectal Cancer Tazi, El Mehdi Essadi, Ismail Boutayeb, Saber M’rabti, Hind Errihani, Hassan Gastroenterology Res Review Article The use of adjuvant chemotherapy has improved survival in early-stage colon cancer. Ongoing adjuvant clinical trials are evaluating the addition of targeted therapies to standard chemotherapy regimen. Preliminary results with bevacizumab were disappointing. Also, cetuximab added to chemotherapy does not seem to be better than chemotherapy alone, even in selected wild-type KRAS populations. A better understanding of mechanisms of action of drugs, tumor biology, and predictive biomarkers are needed to design future adjuvant trials. Elmer Press 2011-08 2011-07-20 /pmc/articles/PMC5139728/ /pubmed/27942334 http://dx.doi.org/10.4021/gr335w Text en Copyright 2011, Tazi et al. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Tazi, El Mehdi
Essadi, Ismail
Boutayeb, Saber
M’rabti, Hind
Errihani, Hassan
Biotherapy in the Adjuvant Treatment of Colorectal Cancer
title Biotherapy in the Adjuvant Treatment of Colorectal Cancer
title_full Biotherapy in the Adjuvant Treatment of Colorectal Cancer
title_fullStr Biotherapy in the Adjuvant Treatment of Colorectal Cancer
title_full_unstemmed Biotherapy in the Adjuvant Treatment of Colorectal Cancer
title_short Biotherapy in the Adjuvant Treatment of Colorectal Cancer
title_sort biotherapy in the adjuvant treatment of colorectal cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139728/
https://www.ncbi.nlm.nih.gov/pubmed/27942334
http://dx.doi.org/10.4021/gr335w
work_keys_str_mv AT tazielmehdi biotherapyintheadjuvanttreatmentofcolorectalcancer
AT essadiismail biotherapyintheadjuvanttreatmentofcolorectalcancer
AT boutayebsaber biotherapyintheadjuvanttreatmentofcolorectalcancer
AT mrabtihind biotherapyintheadjuvanttreatmentofcolorectalcancer
AT errihanihassan biotherapyintheadjuvanttreatmentofcolorectalcancer

Ejemplares similares